OmniAb Q4 revenue $35.3M, net income $6.8M; record 13 new partnerships in 2022

OmniAb, Inc.

Q4 revenue $35.3M (up from $15.3M YoY) driven by $25M TECVAYLI milestone; net income $6.8M vs loss of $3.1M.
Full year 2022 revenue $59.1M (up from $34.7M); net loss $22.3M ($0.26/share) vs $27.0M loss in 2021.
Cash and short-term investments $88.3M at Dec 31, 2022; received additional $35M in Jan 2023 from Janssen.
Signed 13 new licenses in 2022; 26 OmniAb-derived programs in clinic/commercial; 291 total programs.
Expects $10M milestone from TECVAYLI EU approval in 2023; 2023 year-end cash slightly higher than 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OmniAb, Inc. reported financial results for three months and full year ended December 31, 2022.

Period: three months and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 30, 2023, OmniAb Incorporated (the “Company”) issued a press release announcing its financial results for the three months and full year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

OmniAb, Inc. filing history →

Source: SEC EDGAR

accession 0001846253-23-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.